The Ovarian Tumor Tissue Analysis Consortium [33] has demonstrated a clear dose–response relationship between CD8+ tumor-infiltrating lymphocytes (TILs) and improved survival rates in ovarian cancer patients. The gene discussed is CD8A; the disease is neoplasm.